Expanding the Therapeutic Window for Acute Ischemic Stroke

This direction is merged into another direction: therapeutic window constraints (post-stroke motor impairment). Its last version stays readable and citable here.

Version 1 of 166 papers71 conceptsfrozen 2026-10-04

In the treatment of acute ischemic stroke (AIS), the governing mantra is "time is brain." For every minute blood flow is blocked, an estimated 1.9 million neurons die. This biological reality has historically dictated a rigid clinical clock: intravenous thrombolysis (clot-busting drugs) must typically be administered within 4.5 hours, and mechanical thrombectomy (surgical clot removal) within 24 hours.

However, these strict windows exclude a vast population of patients—those who wake up with symptoms, those in rural areas with long transport times, or those who arrive just minutes past the cutoff. Recent research is shifting the paradigm from "treating the clock" to "treating the tissue," using a combination of advanced diagnostics, systemic optimization, and neuroprotective agents to expand the window of viability.

The Diagnostic Challenge of Unknown Onset

Approximately 25% of strokes are "unwitnessed," meaning the exact time of onset is unknown. Under traditional protocols, these patients are often ineligible for thrombolysis because the risk of brain hemorrhage increases as the "age" of the stroke increases.

To solve this, researchers are developing tools to infer the stroke's age from the brain's appearance rather than the patient's watch. Grant Mair and colleagues have pioneered the CT Clock Tool, which quantifies subtle "darkness" (attenuation) changes on standard CT scans to estimate onset time. By identifying patients whose brain tissue still looks "young," clinicians can safely offer treatment even when the clock is unknown.

This effort is being further refined by deep learning. Adam Marcus and Paul Bentley developed a Transformer-based network that simultaneously segments lesions and predicts their age, achieving high accuracy in identifying patients still within the 4.5-hour golden window.

Systemic Optimization: Reducing "Door-to-Needle" Time

Expanding the therapeutic window isn't just a biological problem; it's a logistical one. Even if a patient arrives on time, hospital delays can push them past the eligibility threshold.

Christopher Li Hsian Chen and his team demonstrated that a Quality Control Circle (QCC) approach—integrating EMS protocols with hospital emergency departments—could triple the rate of thrombolysis by streamlining the path from the ambulance to the CT scanner. Similarly, in the context of heart attacks, Liang Wang showed that moving from an "on-call" to a 24/7 on-site surgical team nearly halved treatment delays, proving that organizational synchronization is as vital as medical expertise.

Neuroprotection: Buying Time for the Penumbra

While reperfusion (restoring blood flow) is the goal, neuroprotective agents aim to "freeze" the state of the brain, keeping at-risk tissue (the penumbra) alive until blood flow can be restored.

A network meta-analysis by Mengqi Li identified dl-3-n-butylphthalide (NBP) and Edaravone as leading candidates for this role. NBP, in particular, has been shown to reduce neurovascular inflammation, effectively dampening the "cytokine storm" that follows a stroke.

Researchers are also looking toward traditional and botanical sources to find multi-targeted compounds. For instance, Qian Zhang has documented the mechanisms of Xiaoxuming Decoction, a 1,200-year-old recipe that appears to protect the neurovascular unit through synergistic pathways that modern monotherapies often miss.

Regenerative Medicine in the Subacute Phase

The most radical expansion of the therapeutic window involves moving beyond the first 24 hours into the subacute and chronic phases. When the window for saving existing neurons closes, the window for repair opens.

The MERIT trial, led by Junwei Hao, demonstrated that intravenous transplantation of umbilical cord-derived mesenchymal stem cells (UC-MSCs) is safe and potentially effective even 3 to 6 months after a stroke. These cells don't necessarily "replace" lost neurons; instead, they act as "bioreactors," secreting factors that suppress chronic inflammation and promote the brain's own plastic recovery.

By combining these three pillars—precision diagnostics to identify salvageable tissue, logistical overhauls to speed up delivery, and neuroprotective/regenerative therapies to extend cellular survival—the field is moving toward a future where "time" is no longer the absolute arbiter of a patient's recovery.

Papers in this version

Showing 60 of 66 papers.

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_expanding_the_therapeutic_window_for_acu_d8c159c6,
  title = {Expanding the Therapeutic Window for Acute Ischemic Stroke},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/expanding-the-therapeutic-window-for-acute-ischemic-stroke/rdr_d8c159c650104ff6ad66ddcdf18535ba},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_expanding_the_therapeutic_window_for_acu_d8c159c6_v1,
  title = {Expanding the Therapeutic Window for Acute Ischemic Stroke},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/expanding-the-therapeutic-window-for-acute-ischemic-stroke/rdr_d8c159c650104ff6ad66ddcdf18535ba/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}